St John's Institute of Dermatology, King's College London (Guy's Campus), London SE1 9RT, UK.
St John's Institute of Dermatology, King's College London (Guy's Campus), London SE1 9RT, UK.
Med. 2022 May 13;3(5):273-275. doi: 10.1016/j.medj.2022.04.008.
New therapeutic hope is emerging for people with the rare inherited blistering skin disease recessive dystrophic epidermolysis bullosa (RDEB). Gurevich et al. have reported early-phase clinical trial data evaluating a topical herpes simplex virus 1 vector to restore missing type VII collagen in RDEB skin and heal wounds.
对于患有罕见遗传性水疱性皮肤病隐性营养不良型大疱性表皮松解症(RDEB)的患者,新的治疗希望正在出现。Gurevich 等人报告了评估局部单纯疱疹病毒 1 载体以恢复 RDEB 皮肤中缺失的 VII 型胶原蛋白并治愈伤口的早期临床试验数据。